A Nephrologist's Take on the Effect and Impact of SGLT-2 Inhibitors and GLP-1 RAs on Kidneys

1. Half of chronic kidney disease cases progress to kidney failure, heart failure, cardiovascular disease, or even death.

a) True
b) False

2. The benefits of an SGLT-2 inhibitor to slow the progression of chronic kidney disease exceeds the risks of ketoacidosis, fracture, or dehydration in the elderly.

a) True
b) False

3. SGLT-2 inhibitor medications are shown to reduce the risk of kidney disease progression by 30-40%.

a) True
b) False

4. The benefit(s) of GLP-1 receptor agonists include:

a) Decrease in A1C
b) Decrease in systolic blood pressure
c) Decrease in body weight
d) No increase in hypoglycemic events
e) All of the Above

5. Some side effects of GLP-1 receptor agonists are gastrointestinal distress and eye disorders.

a) True
b) False

6. The following help manage the risk of hyperkalemia when taking an MRA:

a) Use a potassium binder
b) Use of diuretics/SGLT-2 inhibitors
c) Reduce the dose of the MRA
d) All of the Above

7. The traditional approach to manage chronic kidney disease includes prescribing an ACE inhibitor or ARB, then an SGLT-2 inhibitor, ns-MRA, and GLP-1 receptor agonist.

a) True
b) False

8. The following risk(s) need to be considered when prescribing SGLT-2 inhibitor therapy:

a) Volume depletion
b) Hyperkalemia
c) Acute kidney injury
d) Diabetic ketoacidosis
e) All of the above

9. There is an increased incidence of urinary tract infections when taking an SGLT-2 inhibitor.

a) True
b) False